Physician

Matei Paul Socoteanu, M.D.

According to 2025 Medicare claims, Matei Socoteanu, M.D. (NPI: 1629269774) practices medical oncology in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 75601-4717.

Socoteanu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 919 traditional Medicare patients, billed 159,519 HCPCS/CPT codes, and received $2,003,487 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,738 prescription claims across 299 beneficiaries totaling $3,347,320 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 50 records totaling $2,023. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $544,031 to $3,347,320. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,941 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	614	182,188	$1,943,371
2016	804	107,312	$1,627,000
2017	849	92,736	$1,566,583
2018	978	139,252	$2,214,223
2019	1,244	254,309	$3,710,791
2020	1,102	202,249	$2,971,815
2021	1,029	184,502	$2,759,099
2022	1,041	174,339	$2,449,663
2023	972	174,019	$2,276,883
2024	919	159,519	$2,003,487

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	242	1,515	$544,031
2016	213	1,650	$1,122,511
2017	217	1,428	$529,051
2018	235	1,419	$773,886
2019	309	1,734	$2,207,283
2020	344	2,014	$2,878,898
2021	353	1,847	$3,034,835
2022	295	1,643	$2,802,608
2023	303	1,854	$2,638,765
2024	299	1,738	$3,347,320

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	71	$4,775
2016	N/R	28	$1,437
2017	N/R	49	$9,303
2018	N/R	N/R	N/R
2019	N/R	31	$5,837
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	47	$2,571
2023	N/R	39	$9,661
2024	N/R	12	$1,604

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	132	274	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	466	819	$85
80053	Blood test, comprehensive group of blood chemicals	504	1,060	$10
36415	Insertion of needle into vein for collection of blood sample	503	1,069	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	481	963	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	24	637	$375,536
Inlyta	Axitinib	15	450	$308,185
Cabometyx	Cabozantinib S-Malate	12	360	$305,316
Verzenio	Abemaciclib	23	644	$276,502
Erleada	Apalutamide	19	570	$267,213

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	12	$1,604

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	49	$1,071	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$952	Celgene Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matei Paul Socoteanu, M.D.?

Tedicare shows public-source Medicare data for Matei Paul Socoteanu, M.D. (NPI 1629269774), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matei Paul Socoteanu, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Matei Paul Socoteanu, M.D.?

Matei Paul Socoteanu, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Matei Paul Socoteanu, M.D. have Open Payments data?

Matei Paul Socoteanu, M.D. has 50 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.